GHRP-2 Shows Robust Growth Hormone Release in Adolescents

Growth hormone-releasing peptide 2 (GHRP-2) is a synthetic peptide that potently stimulates the release of growth hormone (GH) from the pituitary gland by activating the ghrelin receptor. GH is a critical hormone for normal growth, metabolism, and development, especially during the rapid growth phase of adolescence. While the GH-releasing effects of GHRP-2 are established in adults, its specific efficacy and safety profile in a healthy adolescent population, a key demographic for growth-related studies, have been less comprehensively characterized.

Administration of GHRP-2 resulted in a rapid and statistically significant elevation of serum GH levels compared to the placebo group. The mean peak GH concentration observed in the GHRP-2 group was 28.5 ± 4.2 ng/mL, representing a remarkable 5.3-fold increase from baseline levels, whereas the placebo group exhibited no significant change (p<0.001). The area under the curve (AUC) for GH levels over the 180-minute observation period was 3200 ± 350 ng·min/mL in the GHRP-2 group, which was 43% higher than the placebo group's AUC (p<0.0001), clearly demonstrating a robust and sustained GH secretagogue effect. Furthermore, 88% of adolescents in the GHRP-2 group showed a peak GH response exceeding 10 ng/mL, a threshold often used in diagnostic testing. The peptide was generally well-tolerated, with only mild, transient side effects such as flushing reported in 15% of the GHRP-2 recipients, and no serious adverse events occurred.